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GABAARs and GlyRs are considered attractive drug targets for therapeutic intervention
and are also increasingly recognized in the context of in vitro neurotoxicity (NT)
and developmental neurotoxicity (DNT) testing. However, systematic human-specific
GABAAR and GlyR-targeted drug screening and toxicity testing is hampered due
to lack of appropriate in vitro models that express native GABAARs and GlyRs.
We have established a human pluripotent stem cell line (NT2) stably expressing
YFP-I152L, a halide-sensitive variant of yellow fluorescent protein (YFP), allowing for
fluorescence-based functional analysis of chloride channels. Upon stimulation with
retinoic acid, NT2 cells undergo neuronal differentiation and allow pharmacological
and toxicological evaluation of native GABAARs and GlyRs at different stages of brain
maturation. We applied the cell line in concentration-response experiments with the
neurotransmitters GABA and glycine as well as with the drugs strychnine, picrotoxin,
fipronil, lindane, bicuculline, and zinc and demonstrate that the established in vitro
model is applicable to GABAAR and GlyR-targeted pharmacological and toxicological
profiling. We quantified the proportion of GABAAR and GlyR-sensitive cells, respectively,
and identified percentages of approximately 20% each within the overall populations,
rendering the cells a suitable model for systematic in vitro GABAAR and GlyR-targeted
screening in the context of drug development and NT/DNT testing.
Keywords: YFP-I152L, glycine receptor chloride channel (GlyR), gamma-aminobutyric acid receptor type-A
chloride channel (GABAAR), human pluripotent embryonal teratocarcinoma stem cells, NT2 cells, NT2-N cells
INTRODUCTION
GABA type-A receptors (GABAAR) and strychnine-sensitive glycine receptors (GlyR) are ligand-
gated chloride ion channels that mediate inhibitory neurotransmission in the central nervous
system (CNS). In adult neurons, GABAAR and GlyR ion channels conduct an inhibitory anion
current, mainly carried by chloride (Cl−) upon activation by γ-aminobutyric acid (GABA) and
the amino acid glycine, respectively. In embryonic neurons however, due to a higher intracellular
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chloride concentration compared to adult neurons, receptor
activation causes an outward directed, depolarizing and
excitatory Cl− flux (Webb and Lynch, 2007). GABAARs and
GlyRs are both members of the pentameric ligand-gated ion
channel (pLGIC) family and require five subunits to form a single
functional oligomer. For GABAARs there are 19 genes known
(α1–6, β1–3, γ1–3, δ, ε, θ, pi, and ρ1–3) exhibiting a broad range
of heterogeneity and many hundreds of theoretically possible
subunit combinations (Olsen and Sieghart, 2009). For GlyRs
there are four genes known (α1–3, β) in humans, exhibiting
far less diversity compared to GABAARs (Lynch, 2009). Each
GABAAR or GlyR isoform as well as each subunit combination
has a unique physiological and pharmacological profile. The
subunit combination can change during development, in a
tissue-specific manner or as a consequence of pathophysiological
events (Lynch, 2004; Webb and Lynch, 2007; Esmaeili and
Zaker, 2011; Rudolph and Möhler, 2014; Deidda et al., 2015).
Genetic or molecular perturbation of the channels’ function has
been associated with severe neurological disorders including
neuropathic pain (Lian et al., 2012; Xiong et al., 2012; Chen
et al., 2014), chronic pain sensitization (Harvey et al., 2004;
Zeilhofer, 2005; Lynch and Callister, 2006), hyperekplexia
(Chung et al., 2010; Bode and Lynch, 2014), epilepsy (Meier
et al., 2005; Eichler et al., 2008, 2009; Macdonald et al., 2010),
fragile X mental retardation syndrome (D’Hulst et al., 2006),
learning and memory deficits (Deidda et al., 2015) as well as
neurodegeneration (Kang et al., 2015). In addition, GABAARs
and GlyRs are increasingly acknowledged in the context of
immunomodulation (Stoffels et al., 2011; Gunn et al., 2015),
amyotrophic lateral sclerosis (Martin and Chang, 2012) and
cancer (Neumann et al., 2004; Cuddapah and Sontheimer,
2011). Therefore, GABAARs and GlyRs, including individual
isoforms as well as the various subunit combinations in their
native neuronal environment are increasingly considered highly
attractive drug targets for therapeutic intervention (Alexander
et al., 2015). Due to their fundamental role in inhibitory
neurotransmission GABAARs and GlyRs are increasingly
recognized in the context of neurotoxicity (Suñol et al., 1989;
Hall and Hall, 1999; Narahashi, 2002; Vale et al., 2003; Mohamed
et al., 2004; Islam and Lynch, 2012) and in vitro neurotoxicity
testing (NT) (Talwar et al., 2013; Tukker et al., 2016).
AlthoughGABAARs andGlyRs play fundamental roles during
brain development (Avila et al., 2013, 2014), these receptors have
only sparsely been associated with developmental neurotoxicity
and developmental neurotoxicity (DNT) testing. This is even
more surprising as the incidence of neurological diseases
including learning and developmental disorders has increased
in recent years (May, 2000; Colborn, 2004; Rauh et al., 2006;
Herbert, 2010). At the same time, the number and volume of
worldwide registered and traded chemical substances has also
increased. There is no doubt that developing brain is particularly
vulnerable to damage by chemicals (Rice and Barone, 2000)
and evaluation of chemicals for developmental neurotoxicity is
critical to human health (Grandjean and Landrigan, 2006, 2014).
However, only a very small number of chemicals has been tested
for developmental toxicity in recent years (Middaugh et al., 2003;
Makris et al., 2009), presumably because the current guidelines
for DNT testing exclusively involve animal experiments (OECD,
1997, 2007) that are of poor reproducibility and predictive
quality, low in throughput, prohibitively expensive and limited
with regard to mechanistic insights into the toxicant’s mode of
action (Smirnova et al., 2014).
DNT testing is conducted for identification of chemical-
induced adverse changes in the structure and function of the
developing central nervous system. At present, NT and DNT
testing is only officially acknowledged by regulatory authorities
when done with standardized in vivo animal test methods
and when conducted according to guidelines provided by
the Organization for Economic Cooperation and Development
(OECD). For example, NT testing involves daily oral dosing
of rats for acute, sub chronic or chronic assessments for
28 days, 90 days, 1 year or longer (OECD, 1997). Primary
observations include behavioral assessments and evaluation of
nervous system histopathology. DNT testing evaluates in utero
and early postnatal effects by daily dosing of at least 60 pregnant
rats from implantation through lactation. Offspring are evaluated
for neurologic and behavioral abnormalities and brain weights
and neuropathology are assessed at different times through
adulthood (OECD, 2007). The type of exposure (single or
repeated dose) and the outcome (lethal or nonlethal; immediate
or delayed effects) will result in different classifications for
substances under the Globally Harmonized System (GHS).
Since there are various methods available for toxicological
profiling of GABAARs andGlyRs (Gilbert et al., 2009a,b,d; Talwar
et al., 2013) these receptors can serve as valuable molecular
targets for in vitro developmental neurotoxicity testing (DNT)
and provide mechanistic insights into the neurotoxicants or
developmental neurotoxicants mode of action.
However, systematic screening for potentiating or inhibiting
modulators of GABAARs and GlyRs in the context of drug
development and NT/DNT testing is hampered due to lack of
appropriate in vitro models. Recombinant expression systems
using e.g., human embryonal kidney-derived (HEK293) cells
allow systematic large scale screening for GABAAR and GlyR
modulators in high throughput format (Kruger et al., 2005;
Gilbert et al., 2009a,b,d; Talwar et al., 2013; Walzik et al.,
2015). Despite recombinant models being successful in the
identification of GlyR chloride channel modulators (Balansa
et al., 2010, 2013a,b), these systems lack of fundamental neuronal
genetic programs and cell intrinsic regulators influencing
the functional properties of mature neurons in vivo and are
restricted to physiological, pharmacological and toxicological
analysis of individual GABAARs and GlyRs isoforms in isolation.
Modulators identified or investigated using recombinant
expression systems have been reported to yield contradictive
results comparing recombinant systems and native neurons.
For example, NV-31 an analog of bilobalide, a major bioactive
component of Ginkgo biloba herbal extracts, has been reported to
inhibit recombinant GlyRs but to potentiate native hippocampal
neuron GlyRs (Lynch and Chen, 2008). Hence, screening data
generated using recombinant expression system may be only
partially relevant to GABAARs and GlyRs expressed in vivo
and always require time and resource intensive retesting using
secondary and individual approaches. Terminally differentiated
Frontiers in Molecular Neuroscience | www.frontiersin.org 2 June 2016 | Volume 9 | Article 51
Kuenzel et al. NT2-YFP-I152L Cell Line
neuronal cells of human origin, e.g., primary cells from biopsy
samples are rarely available, enable only a limited number
of experiments and are typically derived from pathogenic
tissue, rendering these cells unsuitable to systematic large-scale
screening for modulators of GABAARs and GlyRs. Neuronal cells
of animal origin such as mouse or rat are widely used for studying
mammalian inhibitory neurotransmission in general and the
physiological properties of GABAARs and GlyRs in particular but
are not optimal for identification of human-specific therapeutic
leads or pharmacological probes as well as for GABAAR and
GlyR mediated neurotoxicity or developmental neurotoxicity
as the physiology of animals may strongly differ from human
physiology. Stem cells including induced pluripotent stem cell
(iPSC) and pluripotent embryonal carcinoma cells provide an
enormous potential for both GABAAR- and GlyR-targeted drug
development and NT/DNT testing as they allow standardized
high-throughput in vitro screening of a large number of
chemicals in maturing and adult human neurons, that is time,
cost and resource-effective.
Human pluripotent NTERA-2 (NT2 or TERA2.cl.SP12)
stem cells are increasingly considered as a suitable model
for in vitro NT and DNT studies (Couillard-Despres et al.,
2008; Hill et al., 2008; Laurenza et al., 2013; Pallocca et al.,
2013; Stern et al., 2014). Upon exposure to retinoic acid, the
cells undergo neuronal differentiation, i.e., mimic the process
of differentiation in the developing brain, and are potentially
suitable to NT/DNT testing at different developmental stages
ranging from non-differentiated stem cells, committed neural
progenitors to differentiated neuronal, so called NT2-N cells,
and glial cells (Lee and Andrews, 1986; Pleasure et al.,
1992; Sandhu et al., 2002; Stewart et al., 2003; Ozdener,
2007; Coyne et al., 2011). Electrophysiological studies and
extracellular recordings with NT2-N cells have demonstrated
voltage-activated calcium, TTX-sensitive sodium and potassium
currents, spontaneous synaptic currents as well as glutamate,
N-methyl-D-aspartate (NMDA), GABA and strychnine-sensitive
glycine-induced currents (Pleasure et al., 1992; Munir et al.,
1996; Neelands et al., 1998; Gao et al., 2004; Coyne et al., 2011;
Laurenza et al., 2013) demonstrating that these cells exhibit
properties similar to those described in native human neurons
thus, making them an excellent experimental model for both
GABAAR- and GlyR-targeted drug development and NT/DNT
testing. Also, a variety of neuronal markers has been reported to
be expressed in differentiated NT2-N cells, including β-tubulin
type III, MAP-2 and synapsin I (Pleasure et al., 1992; Stewart
et al., 2003; Hsu et al., 2014; Saporta et al., 2014; Stern et al.,
2014).
To address the limitations of conventional in vitromodels for
GABAAR- and GlyR-targeted drug, NT/DNT screening as well as
of animal-based in vivo NT/DNT testing approaches described
above, we aimed to establish a cell line stably expressing YFP-
I152L under the control of the human ubiquitin promoter C. The
promoter has been reported to drive selective protein expression
in principal neurons in the mammalian brain (Wilhelm et al.,
2011). NT2 cells have previously been reported to provide a
suitable system for expressing exogenous proteins in terminally
differentiated neurons (Pleasure et al., 1992).
YFP-I152L, an engineered variant of yellow fluorescent
protein (YFP) with greatly enhanced anion sensitivity, is
quenched by small anions and is thus suited to reporting anionic
influx into cells (Galietta et al., 2001). The fluorescent protein
has been successfully applied for structure-function analysis and
compound screening with many different chloride channel types
(Kruger et al., 2005; Gilbert et al., 2009a,b,d; Balansa et al., 2010,
2013a,b; Chung et al., 2010; Gebhardt et al., 2010; Talwar et al.,
2013; Walzik et al., 2015).
We further aimed to apply the cell line in concentration-
response experiments with GABA and glycine as well as with a
selection of chemicals with known toxicity profiles on GABAARs
andGlyRs and to compare GABA and glycine EC50 and drug IC50
values with published electrophysiological data and data from
fluorescence based functional imaging.
To evaluate the suitability of the in vitro model to systematic
large-scale functional screening in the context of GABAAR-
and GlyR-targeted drug development and NT/DNT testing, we
intended to quantify the proportion of GABAAR- and GlyR-
positive cells.
Our in vitro model and methodological approach will
be applicable within a framework of various individual
strategies assessing NT/DNT at different stages during neuronal
differentiation as well as to systematic large-scale in vitro
neurophysiological, -pharmacological and -toxicological
screening with GABAARs and GlyRs that is time, cost and
resource-effective. Furthermore, in the context of in vitro-based
experimental and analytical approaches for NT/DNT prediction,
our methodology can contribute to reduce or even replace
animal experiments and to further promote the concept of the
3Rs in biomedicine (Russell and Burch, 1959).
RESULTS
We have established a recombinant human pluripotent stem
cell line, stably expressing halide-sensitive YFP-I152L under the
control of the human ubiquitin C promoter. The cell line allows
fluorescence-based GABAAR and GlyR-targeted drug screening
and in vitro NT/DNT testing at different stages of neuronal
maturation. The workflow of cell line generation, stem cell
differentiation and functional imaging is shown in Figure 1.
Images of recombinant non-differentiated NT2-YFP-I152L stem
cells and differentiated NT2-N-YFP-I152L cells as well as the
principle of functional imaging using the cells are shown in
Figure 2.
Functional Profiling of GABAARs and
GLyRs in Recombinant NT2-N-YFP-I152l
Cells
To assess whether the generated recombinant stem cell line
is suitable to chloride imaging and functional profiling of
GABAARs and GlyRs, NT2-YFP-I152L cells were differentiated
into neuronal NT2-N- YFP-I152L cells as described in the
Methods section and were seeded at defined density of 2 ×
104 cells in each well of a 96-well plate. Two days later and
approximately 1 h prior to fluorescence imaging, the culture
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medium was completely removed and was replaced by 50 µl
NaCl control solution. The standard NaCl control solution
contained (in mM): NaCl 140, KCl 5, CaCl2 2, MgCl2 1, HEPES
10, glucose 10, pH 7.4 using NaOH. The 96-well plate was
placed onto the motorized stage of a high-content imaging
system and cells were imaged in control solution to record
cellular YFP fluorescence in unquenched state. Because YFP-
I152L is almost insensitive to chloride, its fluorescence intensity
is highest in NaCl solution allowing for optimal focussing into
the optical layer of cells. Subsequently, cells were perfused with
100 µl NaI solution containing increasing concentrations of
FIGURE 1 | Workflow of cell line generation, stem cell differentiation
and functional imaging. (A) Generation of NT2-YFPI52L cell line. NT2 stem
cells were seeded into 60 mm culture dishes and transfected with
ubiquitin-YFP-I152L-encoding vector using the calcium phosphate
precipitation method. YFP-I152L-positive cells were selected over 5 weeks
using the antibiotic geneticin. Subsequently, NT2-YFP-I152L cells were
enriched by flow cytometry (FACS). (B) Neuronal differentiation of human
pluripotent NT2 stem cells and preparation for functional imaging. Cells were
differentiated based on 5-week retinoic acid (RA) treatment and NT2-N cells
were enriched by a double-replating strategy. As a preparatory step for
imaging of GABAAR and GlyR-function, cells were plated into 96-well plates.
(C) Preparation of imaging experiments. Approximately 30 min prior to imaging
experiments, the culture media was removed and replaced by control solution
supplemented with pharmacological drugs. Functional imaging was
conducted as shown in Figure 2.
GABA (0.01–100 µM, Figures 3A,B) or glycine (0.1–1000 µM,
Figures 3C,D). The NaI test solution was similar to NaCl control
solution except that the NaCl was replaced by equimolar NaI.
Cells were imaged throughout the complete procedure of agonist
perfusion for a total of 30 seconds and with an acquisition rate
of 2 Hz. Fluorescence quench was calculated at single cell level
by quantitative analysis as described in the Methods section.
The principle of functional profiling of ligand-gated chloride
channels is depicted in Figures 2D–G. Average time-courses of
quench (mean ± SD, n = 10) following the addition of NaI
plus the indicated GABA or glycine concentrations are shown
in Figures 3A,C, respectively and were constructed by pooling
results from wells exposed to different solutions with 10 cells per
well. Average agonist dose–response curves constructed from the
experiments shown in Figures 3A,C are shown in Figures 3B,D,
respectively. Calculated half-maximal activation concentrations
(EC50) for GABA (1.1 ± 0.2 µM) and glycine (4.3 ± 0.5
µM) are listed in Table 1 and are overall smaller compared
with data from functional Cl− imaging and electrophysiology
previously reported in the literature (see Discussion). However,
Hill coefficients (nH) for GABA (1.8 ± 0.4) and glycine (1.5 ±
0.2) correspond well with data from the literature. Although EC50
values measured in this study are overall smaller compared to
values from the literature, these data demonstrate that the cell
line is suitable to chloride imaging and functional profiling of
GABAARs and GlyRs.
Toxicological Profiling of GABAARs and
GlyRs in Recombinant NT2-N-YFP-I152L
Cells
To evaluate the suitability of the established cell line for
systematic screening for GABAAR and GlyR modulators,
we conducted concentration-response experiments with the
chemicals strychnine, picrotoxin, fipronil, lindane, bicuculline,
and zinc in combination with the neurotransmitters GABA or
glycine. To this end, human pluripotent NT2-YFP-I152L cells
were differentiated into neuronal NT2-N-YFP-I152L cells as
described in the Methods section and were seeded at a density of
2× 104 cells in each well of a 96-well plate. 48 h later, the culture
medium was completely removed and was replaced by 50 µl
NaCl control solution. The cells were imaged in control solution
and during perfusion with 100 µl NaI solution containing 1µM
GABA or 3µM glycine—basically representing half-maximal
activation concentrations—and increasing concentrations of the
drugs strychnine (100 pM–10 µM), picrotoxin (1 nM–100 µM),
fipronil (1 nM–100 µM), lindane (1 nM–100 µM), bicuculline (1
nM–100 µM) and zinc (10 nM–1 mM). Average (mean ± SD,
TABLE 1 | Calculated half-maximal activation concentration and hill
coefficients (EC50, nH) for the used neurotransmitters.
GABA Glycine
EC50 (µM) SD nH SD EC50 (µM) SD nH SD
1.1 0.2 1.8 0.4 4.3 0.5 1.5 0.2
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FIGURE 2 | Images of NT2 and NT2-N cells stably expressing YFP-I152L and principle of functional imaging. (A) Transmission light (left) and fluorescence
image (right) of non-differentiated NT2-YFP-I152L cells after 1 day in vitro (DIV) indicating YFP-I152L-expression in most cells of the depicted population. Scale bar
100 µm. (B,C). Transmission light (left) and fluorescence images (right) of differentiated NT2-N-YFP-I152L cells after 35 days in vitro. Cell clusters (B) and neurites (C),
highlighted by white arrows in the respective fluorescence micrographs, indicate successful differentiation of NT2-YFP-I152L cells into NT2-N-YFP-I152L cells and
demonstrate that stable integration of the YFP-I152L-gene does not interfere with pluripotency of NT2 stem cells and their ability to undergo neuronal differentiation.
Scale bar: 100 µm (B) and 30 µm (C). (D,E) Principle of fluorescence-based functional imaging of ligand-gated chloride channels (LGCC) such as GABAARs and
GlyRs. (F) NT2-N-YFP-I152L cells in control solution (NaCl), captured in unquenched state as reflected in the schematic drawing shown in (D). (G) NT2-N-YFP-I152L
cells in quenched state, recorded upon addition of test solution (NaI) supplemented with the GlyR agonist glycine and as reflected by (E). Scale bar: 50 µm.
n = 10) drug dose–responses are shown in Figures 4, 5.
Calculated half-maximal inhibition concentration (IC50) for the
tested chemicals are summarized in Table 2 and indicate that the
recombinant cell line is suitable to GABAAR and GlyR-targeted
toxicological profiling and identification of ion channel-specific
drugs.
Quantification of the Proportion of
GABAAR and GlyR Positive
NT2-N-YFP-I152L Cells
The applicability of the established recombinant in vitro model
for high-throughput GABAAR and GlyR-targeted screening in
the context of lead identification and NT/DNT testing strongly
depends on the proportion of GABAAR and GlyR positive NT2-
N cells in the whole cell population. A very small percentage
of GABAAR and GlyR expressing NT2-N cells requires a
large number of individual experiments including technical
and biological replicates to be conducted in order to obtain
statistically sound results, potentially compromising the usability
of the established cell line for the envisioned application. To
obtain a robust estimate of the proportions of GABAAR andGlyR
TABLE 2 | Calculated half-maximal inhibition concentration (IC50) for the
tested chemicals indicating that the recombinant cell line is suitable to
GABAAR and GlyR-targeted toxicological profiling and identification of
ion channel-specific drugs.
Drug GABA Glycine
IC50 SD IC50 SD
Strychnine (nM) – – 17.2 7
Picrotoxin (µM) 5.8 0.9 1.1 0.2
Fipronil (µM) 10.8 5.8 1.5 0.9
Lindane (nM) – – 78.1 32.6
Bicuculline (µM) 1.1 0.3 13.4 2.5
Zinc – – – –
positive NT2-N-YFP-I152L cells in the overall cell population,
we calculated the percentage of cells per image indicating
a fluorescence quench of at least 20% upon application of
saturating GABA or glycine concentration. The threshold of 20%
fluorescence quench was chosen because, from our experience,
any measured cellular fluorescence change within a range of−20
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FIGURE 3 | GABA and glycine-induced fluorescence quench in NT2-N cells stably expressing YFP-I152L measured using a fluorescence microscope.
(A,C) Averaged time-courses of quench following the addition of NaI plus the indicated GABA or glycine concentrations, respectively. (B,D) Averaged GABA and
glycine concentration–responses measured from the data in (A,C), respectively, 30 s after receptor activation. In this and the subsequent figures, “% fluorescence
quench” is defined as (F init− Ffinal) × 100 / F init, where F init and Ffinal are the initial and final values of fluorescence, respectively. All data are given as mean ± SD
(n = 10).
to 20% reflects biological noise typical to the employed assay.
As a starting point toward analysing the proportion of GABAAR
and GlyR-positive cells we segmented the images of a total
of 24 individual experiments from two different differentiation
batches (GABAAR, batch #1: n = 7, batch #2: n = 6; GlyR,
batch #1: n = 6, batch #2: n = 5) using a modified version
of DetecTIFF© software (Gilbert et al., 2009c) employing two
individual sets of parameters for the identification of small
neuronal NT2-N-YFP-I152L and larger non-neuronal NT2-
YFP-I152L cells. Figure 6A shows a representative fluorescence
micrograph of large NT2-YFP-I152L and small NT2-N-YFP-
I152L cells, highlighted with white and gray arrows, respectively.
Exemplary segmentation masks created from the image shown in
Figure 6A for quantitative analysis of fluorescence intensity and
calculation of “% fluorescence quench” in small neuronal NT2-
N-YFP-I152L cells and large non-neuronal cells are depicted in
Figures 6B,C. The average cell size (in pixel, mean ± SD) of
GABA or glycine-exposed small and large cells calculated from
two independent differentiation batches is shown in Figure 6D
and is as follows: GABA-exposed small cells: 177 ± 94 (batch
#1, n = 1869) and 152 ± 89 pixel (batch #2, n = 2560), GABA-
exposed large cells: 1369 ± 760 (batch #1, n = 1216) and 1228 ±
709 pixel (batch #2, n= 1371); glycine-exposed small cells: 163±
93 (batch #1, n= 1631) and 158± 92 pixel (batch #2, n= 1071);
glycine-exposed large cells: 1356 ± 757 (batch #1, n = 1212) and
1316± 752 pixel (batch #2, n= 828). In a next step, we calculated
the percentage of cells per image indicating a fluorescence quench
of at least 20% upon application of saturating GABA and glycine
concentration (see histogram in Figure 6E) that is as follows:
GABA-exposed small cells: 28 ± 13 (batch #1, n = 7) and 32 ±
12 % (batch #2, n = 6), GABA-exposed large cells: 3 ± 1 (batch
#1, n = 7) and 6 ± 2% (batch #2, n = 6); glycine-exposed small
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FIGURE 4 | Applicability of the established in vitro model for
pharmacological and toxicological evaluation of GABAAR modulators.
(A–F) Averaged dose-responses (mean ± SD, n = 10) of the chemicals
strychnine, picrotoxin, fipronil, lindane, bicuculline, and zinc, demonstrating the
applicability of the cell line for GABAAR-targeted screening in the context of
drug development and NT/DNT testing. 1 µM GABA concentration, basically
reflecting GABA half-maximal activation concentration, was used in these
experiments.
cells: 36 ± 14 (batch #1, n = 6) and 35 ± 7% (batch #2, n = 5);
glycine-exposed large cells: 2 ± 1 (batch #1, n = 6) and 4 ±
2% (batch #2, n = 5). Approximately one third of the small cell
population is represented by GABAAR and GlyR-positive cells,
equaling 17 ± 8 (GABA, batch #1), 21 ± 9 (GABA, batch #2),
20 ± 9 (glycine, batch #1) and 19 ± 4% (glycine, batch #2) and
rendering ∼20% of the overall population GABAAR and GlyR-
positive cells. These data indicate a population of GABAAR and
GlyR-positive cells that is stable between individual experiments
and differentiation batches, highlighting the applicability of the
established in vitro model for systematic GABAAR and GlyR-
targeted high-throughput pharmacological and toxicological
screening in the context of drug development and NT/DNT
testing.
DISCUSSION
For the sake of feasibility, throughput and cost reasons, GABAAR
and GlyR-targeted screening is typically conducted in non-
neuronal recombinant expression systems assessing individual
GABAARs and GlyRs isoforms in isolation. Such expression
FIGURE 5 | Suitability of the established cell line for pharmacological
and toxicological analysis of GlyR modulators. (A–F) Averaged
dose-responses (mean ± SD, n = 10) of the chemicals strychnine, picrotoxin,
fipronil, lindane, bicuculline, and zinc. 3 µM glycine concentration, reflecting
glycine EC50 concentration, was used in these experiments. These data
further demonstrate the suitable of the generated in vitro model to
LGCC-targeted screening in the context of drug development and NT/DNT
testing.
systems usually also lack fundamental neuronal genetic programs
and cell intrinsic regulators of mature neurons in vivo. The initial
benefit is often compromised by subsequent time-consuming and
cost-intensive re-screens for validation and specificity-evaluation
of potential GABAAR and GlyR-modulators. In the context
of neurotoxicity (NT) or developmental neurotoxicity (DNT)
testing, GABAARs and GlyRs can serve as molecular targets
and can contribute to deciphering the molecular mechanisms
of toxic effects. However, so far there are no suitable in vitro
models available which comprehensively reflect the complex
situation of the central nervous system in vivo and NT/DNT
testing is still solely based on animal experimentation that
is morally questionable, low in throughput, expensive and of
rather poor predictive quality. To address these issues, we have
established a recombinant human pluripotent stem cell line,
stably expressing YFP-I152L that is advantageous for GABAAR
and GlyR-targeted screening in the context of lead identification
and drug development as well as for NT/DNT testing for
several reasons. First, the recombinant cell line allows functional
profiling of GABAARs and GlyRs in neuronal environment,
providing fundamental neuronal genetic programs and cell
intrinsic regulators critical to reflecting the functional properties
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FIGURE 6 | Quantification of the proportions of GABAAR and GlyR-positive NT2-N-YFP-I152L cells. (A) Representative fluorescence micrograph of
NT2-N-YFP-I152L cells in differentiation culture used for functional imaging experiments. (B,C) Exemplary segmentation masks created from (A) for quantification of
“% fluorescence quench” in small NT2-N-YFP-I152L cells (gray arrows, B) and large non-neuronal cells (white arrows, C), respectively. (D) Comparative analysis of the
average cell size (in pixel) of GABAAR and GlyR-positive small neuronal and large non-neuronal cells quantified from two independent differentiation batches each. (E)
Comparative analysis of the average percentage of small NT2-N-YFP-I152L and large non-neuronal cells, responding with at least 20% fluorescence quench upon
exposure to saturating GABA or glycine concentration, respectively. Approximately one third of the small cell population is represented by GABAAR and GlyR-positive
cells, equaling about 20% of the overall population of cells. These data indicate a small proportion of GABAAR and GlyR-expressing cells that is stable between
individual experiments and differentiation batches, further highlighting the applicability of the established in vitro model for systematic GABAAR and GlyR-targeted
high-throughput pharmacological and toxicological screening in the context of drug development and NT/DNT testing. Scale bar: 200 µm.
of mature neurons in vivo. Second, the in vitromodel is of human
origin, allowing for GABAAR and GlyR-targeted screening
relevant to human physiology, including identification of leads
for therapeutic intervention and toxicity evaluation. Third, as
the cell line used in this study mimics brain maturation to a
certain extent, it allows analysis of the physiological properties of
GABAAR and GlyR during development of the central nervous
system. Fourth, the cell model has been applied over a large
range of passages—up to passage number 50 until now—without
noticeable loss in YFP-I152L fluorescence intensity, further
highlighting its applicability to standardized in vitro NT/DNT
testing. Finally, differentiation of NT2 cells can be conducted
in large scale format allowing for systematic high-throughput
experimentation.
We exposed the cell line to GABA or glycine and
demonstrated that the in vitro model is suitable to functional
imaging of both GABAARs and GlyRs. Despite the fact that
Hill coefficients compare well with data from the literature,
the calculated half-maximal activation concentration for GABA
and glycine is overall smaller compared to EC50 concentrations
previously measured in NT2-N cells using whole cell patch
clamp electrophysiology (Neelands et al., 1998; Gao et al.,
2004; Gao and Greenfield, 2005; Coyne et al., 2011). Although
it is difficult to isolate the reason for this without directly
comparing concentration-response data from the same cells
generated with different methodologies, the apparent high GABA
and glycine sensitivities may have been caused by the relatively
long incubation time in agonist solution, i.e., the time between
application of the agonist and quantification of the fluorescence
intensity (30 s). Furthermore, we have previously observed
differences in glycine EC50, i.e., increased sensitivity for glycine,
in recombinantly expressed α1, α2, and α3 GlyR, assessed with
the fluorescence-based assay vs. patch clamp electrophysiology
(Talwar et al., 2013).
We used the recombinant in vitro model in a case
study with the drugs strychnine, picrotoxin, fipronil, lindane,
bicuculline and zinc. The imaging data indicate that YFP-
I152L-expressing NT2-N cells are applicable to GABAAR and
GlyR-targeted toxicological profiling and identification of ion
channel-specific drugs. The drug strychnine specifically inhibited
glycine but not GABA-induced anion-influx with average
IC50 values that correspond very well with results measured
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by either electrophysiological or equilibrium [3H]-strychnine
displacement studies using recombinantly expressed homomeric
wildtype α1 GlyRs and variants (Lynch et al., 1997; Vafa
et al., 1999). Also, concentration-response experiments with
pictrotoxin, a standard pharmacological tool for identifying
the presence of β-subunits in recombinant and native GlyRs
(Lynch, 2004) revealed half-maximal inhibition concentrations
and slope values for glycine and GABA-induced anion influxes,
that correspond well with results measured by patch clamp
electrophysiology in recombinantly expressed homomeric a2
GlyR (Wang et al., 2007) as well as in human pluripotent
stem cell-derived neurons (James et al., 2014), respectively.
The alkaloid is known to strongly inhibit GABAARs at
low micromolar concentrations, whereas GlyRs in vivo are
considered much less sensitive (Lynch, 2004). However, we
observed a reversed sensitivity sequence with a picrotoxin-
sensitivity of GlyR that is approximately 5-fold higher compared
to GABAARs. As it has been reported that αβ-heteromeric
GlyRs were less sensitive to picrotoxin-inhibition than were
α-homomeric GlyRs (Pribilla et al., 1992) we speculate that
NT2-N-YFP-I152L cells predominantly express α-homomeric
GlyR rather than αβ-heteromeric GlyRs, although this is no
explanation for the reversed picrotoxin-sensitivities of GlyRs
and GABAARs. Bicuculline, a purported selective antagonist of
the GABAA receptor, inhibited the GABA-induced fluorescence
quench with a half-maximal inhibition concentration similar
to values revealed from rat primary neurons by whole cell
electrophysiological recordings (Kumamoto and Murata, 1995).
Bicuculline also inhibited glycine induced I− influx in NT2-N-
YFP-I152L cells with about 10-fold lower sensitivity compared
to GABA-dependent anion influx, highlighting its specificity
to GABAAR on the one hand, but also confirming previous
reports on its inhibitory action assessed in both recombinantly
expressed (Sun and Machu, 2000) and native glycine receptors
(Bhattarai et al., 2016) on the other hand. The IC50 value for
glycine-induced fluorescence quench revealed in presence of
increasing concentration of the insecticide lindane is about one
order of magnitude smaller compared to electrophysiological
recordings from recombinantly expressed GlyRs (Islam and
Lynch, 2012). These data suggest that NT2-N-YFP-I152L cells
predominantly express homomeric GlyRs as lindane has proven
to selectively inhibit homomeric but not heteromeric GlyRs
(Islam and Lynch, 2012; Talwar et al., 2013). This conclusion
is further supported by the above mentioned high picrotoxin-
sensitivity of GlyRs. Surprisingly, lindane showed no dose-
dependent inhibitory activity on GABA-induced anion influx,
although lindane-sensitivity of GABAARs has been reported by
many studies conducted in various culture models and cell types
(Narahashi, 1996; Ogata et al., 1988; Vale et al., 2003). A study
conducted by Belelli et al. (1999) demonstrated no effect on
GABA-evoked currents mediated by anesthetic-insensitive wild-
type GABA receptors composed of the (rho 1) subunit (Belelli
et al., 1999), suggesting expression of GABAA rho 1 receptor in
the examinedNT2-N-YFP-I152L cells. Indeed there are a number
of studies indicating profound changes in subunit expression
and pharmacology during neuronal differentiation—similar to
developmental changes in GABAAR occurring in neurons of
the developing central nervous system—and demonstrating
a large variety of neurotransmission phenotypes of non-
differentiated NT2 and differentiated NT2-N cell in vitro
(Neelands et al., 1998, 1999; Guillemain et al., 2000). This
question however was not further evaluated in the present
study. Fipronil, a broad-spectrum insecticide, inhibited both
GABA and glycine induced anion influx in NT2-N cells with
sensitivities that correspond very well to results measured by
patch clamp electrophysiology in recombinantly expressed GlyRs
and GABAAR (Ratra et al., 2001; Li and Akk, 2008; Islam
and Lynch, 2012). Zinc is widely recognized as a modulator
of both, GABAAR and GlyR (Smart et al., 1994). For GlyRs,
potentiation as well as inhibition of glycine-activated currents
by low (<10 µM) and high concentrations (>100 µM) of
zinc, respectively has been reported (Harvey et al., 1999). For
GABAARs, inhibition has been shown at concentrations >10
µM (Kumamoto and Murata, 1995). Although we observed
a minor increase of a glycine-induced fluorescence quench
(Approximately 10%) in presence of 1 and 10 µM zinc, this
effect is not significant. In contrast, zinc-dependent inhibition
was observed at concentrations >100 µM for both GABA and
glycine-induced anion influx, confirming previous reports on
zinc-sensitive GABA-induced currents recorded from NT2-N
cells (Gao et al., 2004). The zinc IC50 could not be calculated due
to a too small range of applied concentrations but presumably
exceeds 1 mM, suggesting the presence of γ subunits which have
shown to confer zinc insensitivity to αβ GABAARs (Smart et al.,
1991).
We quantified the proportion of GABAAR and GlyR positive
NT2-N-YFP-I152L cells based on images of the cells and
we identified a percentage of approximately 20% of cells
expressing GABAARs and GlyRs, respectively. Despite the fact
that the proportion of glycine and GABA sensitive cells are
comparable, it cannot be concluded from our data whether the
cells are simultaneously sensitive to both glycine and GABA
or respond to either of the neurotransmitters. Although the
calculated proportions have proven stable between different
batches of differentiation cultures, the total percentage of
GABAAR and GlyR positive NT2-N-YFP-I152L cells is not
optimal for plate reader, i.e., photomultiplier or cell population-
based screening, that typically requires a high number of reacting,
e.g., GlyR or GABAAR-positive cells and allows experimentation
in high-throughput screening mode. If desired or required,
the proportion of NT2-N-YFP-I152L cells may be increased
by size-exclusion filtering using e.g., a simple nylon filter of
defined mesh size or even more sophisticated cell sorting
approaches. As highlighted by gray and white arrows in
the fluorescence micrograph depicted in Figure 6A and the
histogram shown in Figure 6D, NT2-N cells are much smaller
compared to non-neuronal cells, presumably facilitating size-
dependent population-increase of NT2-N cells. Despite the fact
that plate reader-based screening allows experimentation in high
or even ultra-high-screening mode it is disadvantageous with
regard to cellular heterogeneity. Cultures of NT2 cells have been
reported to express a large variety of non-neuronal and neuronal
phenotypes (Guillemain et al., 2000), as we have shown in the
case study using drugs with known and partly GABAAR and
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GlyR-specific pharmacological and toxicological profiles. Besides
their neuronal properties and human origin, the heterogeneity
of NT2-N cell cultures is probably one of the most important
advantages over homogeneous, e.g., recombinant expression
systems, as it reflects the in vivo situation to a much higher extent
than simplifying in vitro models. Thus, microscopy-based high-
content imaging of NT2-N cells, evaluating the physiological
pharmacological and toxicological properties at single cell level,
and in the context of cellular heterogeneity, is likely to be the
optimal approach for systematic GABAAR and GlyR-targeted
drug screening as well as NT/DNT testing.
To confirm the validity of the morphology or size-
based selection criterion, we conducted functional imaging
experiments with non-treated NT2-YFP-I152L stem cells and
quantified the average cell size as well as the percentage of
stem cells, responding with at least 20% fluorescence quench
upon exposure to saturating GABA or glycine concentration,
respectively (see Supplementary Figure S1). The average cell size
(pixel), calculated from two individual experiments each (see
Supplementary Figure S1C) is comparable between experiments
(GABA, replicate #1: 397 ± 254 pixel, n = 650 cells, replicate
#2: 385 ± 252 pixel, n = 547 cells; glycine, replicate #1:
403 ± 243 pixel, n = 589, replicate #2: 400 ± 256 pixel,
n = 654) and differs from the size of small and large cells,
respectively, as indicated in Figure 6D. The percentage of non-
treated NT2-YFP-I152L stem cells, responding with at least 20%
fluorescence quench upon exposure to 1 mM saturating GABA
(replicate #1: 0.62%, replicate #2: 0.37%) or glycine (replicate
#1: 0.68%, replicate #2: 0.92%) concentration, respectively (see
Supplementary Figure S1D), also differs considerably from data
obtained with retinoic acid-exposed NT2-N-YFP-I152L cells.
These data clearly demonstrate that the morphology, e.g., the
size, as well as the functional properties, i.e., the sensitivity to
GABA or glycine, vary between non-treated stem cells and NT2-
YFP-I152L differentiation cultures containing small neuronal
and large non-neuronal cells and confirming the validity of the
employed size-based selection criterion.
We have previously published a method allowing for
assessment of ligand-gated ion channels in the context of cellular
heterogeneity that is based on progressive receptor activation and
iterative fluorescence imaging (Talwar et al., 2013). This method
could easily be adapted for application with the established
in vitro model and has the power to deliver imaging data
of unsurpassed functional content presumably outranging any
other existing technique for assessing physiological properties of
ion channels with regard to throughput.
Due to the fact that our method is based on microscopic
evaluation using a single fluorescence indicator, it allows
additional fluorescence or luminescence-based markers to be
implemented formultiplexing, such as ion or pH-sensitive probes
e.g., for parallel analysis of further ion channels or transporters, to
assess the activity of intracellular, e.g., toxicity-relevant signaling
pathways, or for mapping cellular morphology to functional
phenotypes.
It is important to mention that the applicability of the
cell line as well as the experimental approach depends on
the proteins to be evaluated and targeted, on the individual
experimental setup, the available instrumental infrastructure
and the biological question to be assessed. While this work
focuses on functional profiling and GABAAR and GlyR-targeted
drug screening as well as neurotoxicity and developmental
neurotoxicity, our in vitro model and methodological approach
could also be adapted for other proteins and strategies, such as
RNAi or combined compound and RNAi screening, for single-
endpoint or time-resolved functional expression analysis or for
approaches using overexpression libraries. Altogether, this work
contributes to furthering the applicability of cell-based high-
throughput functional screening and provides a means for large-
scale characterization of neuronal proteins in the context of in
vitro-based NT/DNT prediction thus, promoting a systems-level
understanding of human physiology in homeostasis and disease.
METHODS
Pharmacological Reagents
Glycine, GABA, strychnine, picrotoxin, fipronil, lindane, zinc
chloride and bicuculline were obtained from Sigma. Stock
solutions of glycine (1M), GABA (1M) and zinc chloride
(1M) were prepared in water, strychnine (10mM), picrotoxin
(100mM), fipronil (30mM), lindane (30mM) and bicuculline
(100mM) were dissolved in dimethylsulphoxide (DMSO). All
stocks were frozen at −20◦C. From these stocks, solutions for
experiments were prepared on the day of recording.
Reagents for Differentiation of NT2
Pluripotent Stem Cells
Retinoic acid and poly-D-lysine (PDL) were obtained from
Sigma. Retinoic acid was prepared as 100mM stock in DMSO.
Uridine was prepared as 100mM stock in water. These stocks
were kept at −80 to −20◦C. PDL was prepared as 10x stocks
in water and stored at 4◦C. Solutions for differentiation cultures
were prepared freshly at the days of experimentation.
Molecular Constructs
The regulatory region of the human ubiquitin C promoter
(1204 bp) was amplified by PCR, the vector pFUGW (Addgene)
was used as the template as well as specific primers (Invitrogen).
The fragment was then inserted into the promoterless vector
pDsRed2-1 (Clontech). PCR of the YFP-I152L gene (720 bp)
was performed using vector pcDNA3.1-YFPI152L (Invitrogen)
as a template and specific primers (Invitrogen). The YFP-I152L-
coding construct was kindly provided from Prof. Joe Lynch
(Queensland Brain Institute, The University of Queensland,
Brisbane, Australia). After removing the sequence of the red
fluorescent protein from the vector phuUbC-DsRed2, YFP-I152L
was sub-cloned into the vector. The expression of YFP-I152L is
under the control of the constitutive active human ubiquitin C
promoter, the plasmid carries the neomycin resistance gene for
the selection with the antibiotic geneticin.
Cell Line
Human pluripotent teratocarcinoma NT2 cells (NTERA-2 cl.D1,
CRL-1973TM) were purchased from The American Type Culture
Collection (ATCC).
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Generation of Stable Cell Line
For generating a cell line stably expressing YFP-I152L, NT2
stem cells were seeded into 60 mm culture dishes (TPP) at
a density of 5 × 105 cells and were incubated at standard
conditions over night. The next day, cells were transfected
with ubiquitin-YFP-I152L-encoding vector using the calcium
phosphate precipitation method. YFP-I152L-positive cells were
selected over 5 weeks with 0.5mg/ml geneticin (Roth, Germany).
The geneticin concentration had previously been examined
in a concentration-response experiment with 0.1–1.0mg/ml
geneticin by measuring the fluorescence intensity of Hoechst
33342 stained (1µM) cells exposed to geneticin for 48 h
in 96-well plate format using a VICTOR X4 plate reader
(Perkin Elmer). The kill curve for evaluation of the geneticin
concentration is shown in Figure 1A, subpanel #2. Geneticin-
selected NT2-YFP-I152L cells with strongest fluorescence signal
were enriched by flow cytometry (FACS, approximately top 30%,
see Figure 1A, subpanel #3) in a single step. Enriched cells were
maintained in geneticin-supplemented medium at the above
mentioned concentration until initiation of the differentiation
procedure. Recombinant cells were used over a large range of
passages between passage number 15 and 50, without noticeable
decline in YFP-I152L fluorescence intensity.
Cell Culture
Cells were maintained in DMEM (Invitrogen) supplemented
with 10% fetal bovine serum (FBS, Biochrom) and penicillin
(100U/ml)/streptomycin (100mg/ml) (Invitrogen) and were
cultured in T75 flasks (TPP) at 37◦C, 5% CO2 in a humidified
incubator according to standard procedures. Cells were passaged
every 2–3 days and used in differentiation cultures when
approximately 80–90% confluent.
Differentiation Culture
We have previously developed an optimized method for
neuronal differentiation of human pluripotent NT2 stem cells
in monolayer cultures. In brief, NT2 cells were seeded at a
defined density into PDL coated 60 mm dishes (TPP) in standard
culture medium supplemented with 10% FBS and penicillin
(100U/ml)/streptomycin (100mg/ml) and 10 µM RA and were
cultured for 5 weeks at 37◦C, 5% CO2 in a humidified incubator.
In the second week, 10 µM uridine was added to the media.
Preparation of Cells for Experiments
Following retinoic acid treatment, cells were replated into T25
flasks and cultured overnight at standard conditions. The next
day, NT2-N-YFP-I152L cells located on top of non-differentiated
cells were removed by tapping and were seeded at a density of
2 × 104 into the wells of a BD MatrigelTM matrix (BD) coated
96-well plate. Cells were used in functional imaging experiments
48 h later.
Preparation of Imaging Experiments
Approximately 1 h prior to commencement of experiments
culture media in 96-well plates was removed manually and was
replaced by 50µl standard control solution, which contained
(in mM) NaCl 140, KCl 5, CaCl2 2, MgCl2 1, HEPES 10, and
glucose 10 (pH 7.4, NaOH) upon washing the cells once in 50
µl standard control solution. The NaI test solution was similar
in composition to NaCl control solution except the NaCl was
replaced by equimolar NaI. For imaging experiments the agonist
NaI test solution was supplemented with 1 mM glycine or
GABA and was serially diluted with NaI test solution to obtain
agonist solutions containing 0.01, 0.03, 0.1, 0.3, 1, 3, 10, 30, 100
µM final GABA or 0.1, 0.3, 1, 3, 10, 30, 100, 300 and 1000
µM final glycine concentration. For antagonist concentration-
response experiments, the control solution was supplemented
with 1µMGABA or 3µMglycine and increasing concentrations
of either of the drugs strychnine (100 pM–10 µM), picrotoxin
(1 nM–100 µM), fipronil (1 nM–100 µM), lindane (1 nM–100
µM), bicuculline (1 nM–100 µM) and zinc (10 nM–1 mM). All
drugs were diluted from stocks at the day of the experiment and
experiments were conducted at room temperature.
Imaging Infrastructure
The 96-well plate was placed onto the motorized stage of a high-
end long-term imaging system (Nikon Eclipse Ti, Nikon, Japan)
and was imaged with a 10x objective (CFI Plan Fluor DL 10X
Phase, N.A. 0.30, Nikon, Japan). Illumination from a xenon lamp
(Lambda LS, Sutter Instruments, USA), passing through a filter
block (C-FL Epi-FL FITC, EX 465-495, DM 505, BA 515-555,
Olympus, Japan) was used to excite and detect YFP fluorescence
signal. Fluorescence was imaged by a sCMOS camera (NEO,
Andor, Ireland) and digitized to disk onto a personal computer
(Dell Precision T3500, Dell, USA) with Windows 7 operating
System (Microsoft Corporation, USA). The primary resolution of
the camera was 2560 × 2160 pixel, although images were binned
(2× 2), resulting in a resolution of 1280× 1080 pixel. Each image
typically contained 350–700 cells. The CCD image acquisition
rate was 2Hz.
Imaging Experiments
The experimental protocol involved imaging each well for 30 s at
2Hz acquisition rate capturing the initial fluorescence intensity
in the control situation as well as the test situation upon
receptor activation, respectively. Liquid handling was performed
manually.
Single Cell-Based Quantitative Image
Analysis
Cells depicted in fluorescence micrographs were selected
manually based on strongest quench for low and intermediate
concentrations and based on cell morphology in experiments
where high drug concentrations were applied. Registered images
of fluorescent cells were segmented and quantitatively analyzed
using NIS-Elements software (Nikon, Japan). The fluorescence
signal of identified cells was measured in images acquired before
and after the addition of agonist solution as the mean of all
pixel values within the area of a cell. “% fluorescence quench” in
chloride imaging experiments is defined as
%fluorescence quench =
(
Finit − Ffinal
)
∗ 100/Finit
where Finit and Ffinal are the initial and final values of
fluorescence, respectively.
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Calculation of Concentration-Response
Relationships
Individual concentration responses were constructed by pooling
results from ten cells in one well exposed to agonist solution.
Concentration-response relationships were fitted with the
following equation:
F = Fmax+
Fmin− Fmax
1+ ([Agonist]/EC50)nH
where F is the fluorescence corresponding to a particular agonist
concentration, [Agonist]; Fmin and Fmax are the minimal
and maximal fluorescence values, respectively; EC50 is the
concentration that elicits half-maximal activation; and nH is the
Hill coefficient. Curve fits were performed using a least squares
fitting routine (Origin 7G, OriginLab Corporation). All averaged
results are expressed as mean± SD.
Quantification of the Proportion of
GABAAR and GlyR-Positive Cells
Images of fluorescent cells were segmented and quantitatively
analyzed using a modified version of DetecTIFF R© software
(Gilbert et al., 2009c). In brief, images were segmented using an
iterative size and intensity-based thresholding algorithm and the
fluorescence signal of identified cells was calculated as the mean
of all pixel values within the area of a cell.
Data Analysis and Visualization
Imaging data were annotated in Microsoft Excel and analyzed
using Origin 7G (OriginLab Corporation).
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